Mobia Medical, Inc.·4

May 11, 9:58 PM ET

Tansey Casey M 4

Research Summary

AI-generated summary

Updated

Mobia Medical (MOBI) Director Casey M. Tansey Buys 66,666 Shares

What Happened
Casey M. Tansey, a director (reported as the managing partner of related investment vehicles), reported an open‑market purchase and multiple conversions of derivative securities into common stock. The clearest cash purchase was 66,666 shares at $15.00 per share on 2026-05-11 for $999,990. The filing also shows multiple derivative grants and conversions reported earlier and on 2026-05-11, including grants on 2026-02-06 (3,769,090.08 derivative shares) and 2026-02-10 (2,000,000 derivative shares) and several conversion line items on 2026-05-11 (e.g., 166,666; 314,090; 3,312,736 and additional conversion/disposition entries totaling several million shares). Footnotes tie many conversions to automatic conversions at the company’s IPO.

Key Details

  • Transaction dates & prices: Open‑market purchase 66,666 shares on 2026-05-11 at $15.00 ($999,990). Multiple derivative grants reported 2026-02-06 and 2026-02-10; several conversions reported on 2026-05-11 (see Form 4 for full line‑by‑line counts).
  • Shares reported after transactions: the filing discloses shares held by related USVP funds totaling 3,626,826 shares (1,623,245 + 1,906,809 + 96,772) per footnote; the reporting person disclaims direct beneficial ownership except for any pecuniary interest.
  • Notable footnotes: F1 explains convertible notes automatically converted at the IPO (conversion price = lower of 80% of offering price or a valuation-based formula). F5 notes certain preferred shares converted to common immediately before the offering. F6 notes some transactions occurred prior to registration and are reported under Rule 16a-2(a). F7 notes a stock option grant vests over three years. F3–F4 describe the reporting person’s role (managing partner) and voting/dispositive power for the funds.
  • Filing timeliness: The report was filed 2026-05-11 while the Period of Report includes transactions back to 2026-02-06, indicating the Form 4 covers earlier grants and appears to have been filed after some of those grant dates.

Context

  • The large, multi‑million share line items are primarily conversions of pre‑IPO instruments (convertible notes and preferred stock) into common stock per the IPO terms — these are corporate capital‑structure changes more than routine buy/sell signals.
  • The $999,990 open‑market purchase is the clearest outright personal buy (a straightforward cash purchase, often viewed by investors as a more direct bullish signal than restructurings).
  • The reporting person is the managing partner of the investment vehicles listed; the filing attributes shares to those funds and includes a standard disclaimer of personal beneficial ownership except for pecuniary interest.

For exact line‑by‑line counts and the company’s specified conversion mechanics, see the Form 4 and its footnotes (Accession 0001628280-26-033820).